Learn how Catalina insights can help you personalize messaging and deliver them to targeted segments for maximum ROI.
Kevin Hunter, Catalina’s Chief Commercial Officer and Head of Innovation, advises CPG marketers and retailers to lean into these five growth strategies in 2023: Connected TV, Shopper Marketing, In-store Incentives, Next Gen Personalization, and Omni-Channel Delivery and Optimization.
Catalina has introduced Catalina Reach Extender, which amplifies current digital offers by extending relevant printed offers at check-out to those who shop exclusively In-store. The retail data science, insights, and media company, 84.51°, is an early collaborator. 84.51° currently delivers personalized promotional offers to Kroger’s digitally engaged shoppers via its website, mobile app, and more broadly via its Loyal Customer Mailer.
During the final quarter of 2022, even as the U.S. grappled with a “tripledemic” of flu, RSV and COVID-19, unit sales of vitamins and health supplements declined over the prior year while average unit prices rose, according to shopper intelligence leader Catalina. A clear exception was Herbal Immune Supplements, unit sales of which shot up 48% while their average price declined by 4%.
During the final quarter of 2022, even as the U.S. grappled with a “tripledemic” of flu, RSV and COVID-19, unit sales of vitamins and health supplements declined over the prior year while average unit prices rose. A clear exception was Herbal Immune Supplements, unit sales of which shot up 48% while their average price declined by 4%.
New insights from Catalina show that the 'tripledemic' is having a large impact on OTC medicine sales. Data Catalina shows that overall over-the-counter (OTC) cold and flu medicine increased in price by 12% in 2022, with private label sales slightly decreasing outside of the children’s category.
The U.S. “tripledemic” is in full swing causing unit sales of over the counter (OTC) treatment categories to rise by as much as 70%. New COVID variants, an early and more serious flu season, plus a sharp uptick of respiratory virus infections (RSV) contributed to OTC cough, cold, RSV, and flu symptom-related products climbing an average of 19% for October-November 2022 compared to the same period a year ago.
The U.S. 'tripledemic' is in full swing causing unit sales of over the counter (OTC) treatment categories to rise by as much as 70%. New COVID variants, an early and more serious flu season, plus a sharp uptick of respiratory virus infections (RSV) contributed to OTC cough, cold, RSV, and flu symptom-related products climbing an average of 19% for October-November 2022 compared to the same period a year ago.